The market is down Thursday over concerns on China’s GDP growth, which could not be offset by a drop in jobless benefit applications. The Dow Jones Industrial Average is down 0.77%, the NASDAQ is down 1.60% and the S&P 500 is down 1.07%. Today’s lone winner was a pharmaceutical company which entered into an agreement to provide a new drug, while weak earnings reports beat up today’s two losers.
Here are today’s market winners and losers.
Biggest Winners
Shares of Affymax (NASDAQ: AFFY) are up 12.12% to $13.41 on trading volume of 1.3 million shares. The company announced Thursday it has entered into a nine-month supply agreement with Takeda to provide the OMONTYS Injection to Fresenius Medical Care North America. The 52-week high is $16.25.
Biggest Losers
Shares of Supervalu (NYSE: SVU) are down 43.29% to $3.00 based on trading volume of 35.3 million shares. The groery store chain’s earnings per share in the first quarter were 19 cents, well short of 38 cents analysts polled by Thomson Reuters expected. The firm also said it was suspending its dividend and would consider selling the company. Before Thursday, the 52-week low was $4.05
Shares of InfoSys (NASDAQ: INFY) are down 12.57% to $38.56 on trading volume of 4.6 million shares. Revenue in the first quarter was $1.75 billion, slightly lower than $1.77 billion Wall Street analysts polled by Thomson Reuters were expecting. Before Thursday, the 52-week low was $41.40.
Samuel Weigley
“The Next NVIDIA” Could Change Your Life
NVIDIA has returned 250-fold in the past 10 years as artificial intelligence took off.
But if you missed out on NVIDIA’s historic run, your chance to see life-changing profits from AI isn’t over.
The 24/7 Wall Street Analyst who first called NVIDIA’s AI-fueled rise in 2009 just published a brand-new research report named “The Next NVIDIA.”
The report outlines key breakthroughs in AI and the stocks ready to dominate the next wave of growth. The report is absolutely free. Simply enter your email below
By providing your email address, you agree to receive communications from us regarding website updates and other offerings that may be of interest to you.
You have the option to opt-out of these emails at any moment. For more information, please review our Disclaimer and Terms of Use.